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Abstract
Background: Treatment of juvenile idiopathic arthritis (JIA) with disease-modifying antirheumatic drugs (DMARDs)
may improve outcomes compared to conventional therapy (e.g., non-steroidal anti-inflammatory drugs, intra-
articular corticosteroids). The purpose of this systematic review was to evaluate the comparative effectiveness and
safety of DMARDs versus conventional therapy and versus other DMARDs.
Results: A systematic evidence review of 156 reports identified in MEDLINE
®, EMBASE
®, and by hand searches. There is
some evidence that methotrexate is superior to conventional therapy. Among children who have responded to a
biologic DMARD, randomized discontinuation trials suggest that continued treatment decreases the risk of having a
flare. However, these studies evaluated DMARDs with different mechanisms of action (abatacept, adalimumab, anakinra,
etanercept, intravenous immunoglobulin, tocilizumab) and used varying comparators and follow-up periods. Rates of
serious adverse events are similar between DMARDs and placebo in published trials. This review identified 11 incident
cases of cancer among several thousand children treated with one or more DMARD.
Conclusions: Few data are available to evaluate the comparative effectiveness of either specific DMARDs or
general classes of DMARDs. However, based on the overall number, quality, and consistency of studies, there is
moderate strength of evidence to support that DMARDs improve JIA-associated symptoms. Limited data suggest
that short-term risk of cancer is low.
Keywords: Juvenile rheumatoid arthritis, Disease-modifying antirheumatic drugs, Comparative effectiveness
research, Systematic review
Background
Non-steroidal anti-inflammatory drugs (NSAIDs) and cor-
ticosteroids (systemic or intra-articular) are only partially
effective in treating the symptoms of juvenile idiopathic
arthritis (JIA) and its long-term complications. Treatment
with disease-modifying antirheumatic drugs (DMARDs)
are increasingly used because they appear to lead to better
disease control. DMARDs, which interfere directly with
immune cells or their function to reduce inflammation,
are typically classified as either biologic (i.e., created by
biologic processes) or non-biologic drugs, also referred to
a ss y n t h e t i cD M A R D s .T a b l e1l i s t st h ec o m m o n l yu s e d
DMARDs, their mechanism of action, and whether they
have been approved for use in children by the U.S. Food
and Drug Administration (FDA). Methotrexate is often
considered a component of conventional treatment, along
with NSAIDs and corticosteroids.
To inform clinicians, patients, and families about the
evidence regarding the management of JIA with DMARDs,
and to help researchers identify critical gaps in knowledge,
the Agency for Healthcare Research and Quality (AHRQ)
commissioned a comparative effectiveness review (CER)
[1]. This report summarizes the central findings from that
CER review about the effects of DMARDs in children with
JIA. Because treatment and outcomes can vary by category
of JIA, we attempted to separately analyze these when data
were available, following the International League of Asso-
ciations for Rheumatology classification (i.e., systemic
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any medium, provided the original work is properly cited.arthritis, oligoarthritis, rheumatoid factor-negative polyar-
thritis, rheumatoid factor-positive polyarthritis, psoriatic
arthritis, enthesitis-related arthritis, undifferentiated JIA)
[2].
Safety is an especially important concern because the
FDA has placed a box warning on the DMARDs that
target tumor necrosis factor alpha (TNF-a) (e.g., etaner-
cept, infliximab, adalimumab), because of concerns
about increased risk of malignancy. Although there are
other potential safety issues, we focus in this summary
report only on the risk of cancer and death.
In this summary, we address the following key
questions:
1. Does treatment with DMARDs compared to con-
ventional treatment with or without methotrexate
improve laboratory measures of inflammation, radiologi-
cal progression, symptoms, or health status?
2. What are the comparative effects of different
DMARDs on these health outcomes?
3. Do the rate and type of serious adverse events differ
between DMARDs or between DMARDs and conven-
tional treatment with or without methotrexate?
4. How do the efficacy, effectiveness, and safety of
treatment with DMARDs differ across categories of JIA?
Methods
Search strategy and identification of relevant studies
We searched MEDLINE
® (1966 through December 2010)
and EMBASE
® (1947 through December 2010) using
Medical Subject Headings (MeSH) terms and key words
for JIA and its older designations (i.e., juvenile rheumatoid
arthritis [JRA], juvenile chronic arthritis [JCA]), the gen-
eric and brand names DMARDs, and the names of instru-
ments used to assess outcomes. The complete search
strategy is available in the CER [1]. The search was limited
to English-language reports of human studies. These
searches were supplemented by review of the bibliogra-
phies of included studies and searches for publications of
potentially eligible studies from abstracts presented in
2008 and 2009 at meetings of the American College of
Rheumatology (ACR), the European League Against Rheu-
matism, and the Pediatric Academic Societies.
Study selection
For efficacy, we included studies with a sample popula-
tion of individuals 18 years or younger with JIA treat-
ment for at least 3 months that included a comparator.
To better understand the potential risk for serious
adverse events, we also included case reports and letters
Table 1 DMARDs Evaluated
Generic name Mechanism of action FDA-approved for JIA?*
Biologic
Abatacept T-cell co-stimulation modulator; soluble fusion protein Yes
Adalimumab TNF inhibitor; anti-TNF monoclonal antibody Yes
Anakinra IL-1 receptor antagonist No
Canakinumab IL-1 inhibitor; anti-IL-1beta monoclonal antibody No
Etanercept TNF inhibitor; fusion protein TNF receptor inhibitor, Yes
Infliximab TNF inhibitor; anti-TNF monoclonal chimeric antibody No
IVIG Interaction with activating Fc receptors No
Rilonacept IL-1 inhibitory; soluble fusion protein No
Rituximab Binds to CD20 antigen No
Tocilizumab IL-6 receptor antagonist No
Non-Biologic
Azathioprine Purine synthesis inhibitor No
Cyclosporine A Calcineurin inhibitor No
Penicillamine Unknown (may lower IgM rheumatoid factor, depresses T-cell activity) No
Hydroxy-chloroquine Not well understood, may reduce T-lymphocyte transformation and chemotaxis No
Leflunomide Isoxazole immunomodulatory agent No
Methotrexate Unknown (anti-metabolite, inhibits dihydrofolic acid reductase) Yes
Mycophenolate mofetil Guanosine synthesis inhibitor No
Sulfasalazine Unknown Yes
Tacrolimus (FK506) Calcineurin inhibitor No
Thalidomide Unknown No
*Labeling refers to any pediatric approval
Abbreviations: CD cluster of differentiation, Fc fragment crystallizable, FDA U.S. Food and Drug Administration, IgM immunoglobulin M, IL interleukin, IVIG
intravenous immunoglobulin, JIA juvenile idiopathic arthritis, T-cell/-lymphocyte thymus cell/lymphocyte, TNF tumor necrosis factor
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abstracts for potential inclusion. The full texts of all
potentially eligible reports were evaluated for inclusion
by two independent reviewers. Differences were resolved
by consensus.
Data extraction
Abstractors worked in pairs: the first abstracted the data,
and the second over-read the article and the abstraction to
assure accuracy. To evaluate response to therapy, disease
activity, and functional status, we abstracted data from
commonly used measures including the ACR Pediatric 30,
50, 70, 90, or 100 response [3], active joint count, time to
flare, remission or inactive disease, the physician global
assessment of disease activity by visual analog scale (0 to
100 mm, with higher scores indicating greater disease
activity), parent or patient global assessment of well-being
by visual analog scale, and the Childhood Health Assess-
ment Questionnaire (CHAQ), which measures functional
ability [4]. For trials that evaluated efficacy, the abstractors
also assessed study quality, generating a summary rating
of good, fair, or poor. These ratings considered allocation,
blinding, outcome assessment, and follow-up, using meth-
ods defined by AHRQ [5]. The rating and corresponding
rationale for each study is available in the CER [1].
Results
Literature search and screening
We identified 4815 citations, of which 156 met eligibility
criteria for at least one of the key questions. Figure 1 illus-
trates the selection process. Figure 2 summarizes the treat-
ment comparisons from the included efficacy studies. Six
non-biologic DMARDs and seven biologic DMARDs have
been compared to conventional treatment with or without
methotrexate. Three different sets of non-biologic
DMARDs have been directly compared (leflunomide vs.
methotrexate, hydroxychloroquine vs. penicillamine, and
hydroxychloroquine vs. sulfasalazine), and two biologic
DMARDs have been directly compared (etanercept vs.
infliximab). Because gold is rarely used in the treatment of
JIA, we did not consider it among the therapies. However,
we do describe its use in the included studies. Three of the
biologic DMARDs that have been compared to conven-
tional treatment were in the same class (TNF-a inhibitors:
adalimumab, etanercept, and infliximab). Study heteroge-
neity precluded meta-analysis of this combined class ver-
sus conventional treatment.
DMARDs vs. Conventional therapy (key question 1)
Biologic DMARDs vs. Conventional treatment with or
without Methotrexate
Abatacept
One good-quality randomized discontinuation study eval-
uated abatacept in children with persistent oligoarthritis,
extended oligoarthritis, polyarthritis, or systemic JIA [6].
During the 6-month double-blind period of this study,
there was statistically significant improvement compared
to placebo in the active joint count (4.4 vs. 6; p = 0.02),
CHAQ score (0.8 vs. 0.7; p = 0.04), physician global assess-
ment (14.7 vs. 12.5; p < 0.01), and ACR Pediatric 90
response (40% vs. 16%; p < 0.01). There was no statistically
significant improvement in parent or patient global assess-
ment (17.9 vs. 23.9; p = 0.70) or erythrocyte sedimentation
rate (ESR; 25.1 vs. 30.7; p = 0.96).
Adalimumab
One good-quality randomized discontinuation trial com-
pared adalimumab to conventional therapy among chil-
dren with polyarticular JRA [7]. The results were
stratified by use of methotrexate. At the end of the 48-
week double-blind phase, fewer patients treated with
adalimumab and methotrexate had flares than those
treated with placebo plus methotrexate (43% vs. 71%; p
= 0.03). Similarly, the proportion of patients who had a
flare of disease in the adalimumab without methotrexate
group was lower than in the placebo group without
methotrexate (37% vs. 65%; p = 0.02). The ACR Pedia-
tric 50 response in the adalimumab without methotrex-
ate group was higher than in the placebo without
methotrexate group (53% vs. 32%; p = 0.01), and higher
than in those groups that received methotrexate (63%
v s .3 8 % ;p=0 . 0 3 ) .A l t h o u g ht h eA C RP e d i a t r i c9 0
response was higher in the adalimumab without metho-
trexate group than in the placebo without methotrexate
group (30% vs. 18%), the difference was not statistically
significant (p = 0.28). Similarly, the ACR Pediatric 90
response among those who also received methotrexate
was higher in the adalimumab group than in the placebo
group, but did not achieve statistical significance (42%
vs. 27%; p = 0.17).
Anakinra
One poor-quality randomized discontinuation trial com-
pared anakinra to conventional therapy among children
with polyarticular, pauciarticular, or systemic JIA [8]. The
main goal of the study was to evaluate safety. By week 28
of blinded treatment, 16% who received anakinra and 40%
who received placebo had had a flare (p = 0.11). There
was improvement in the CHAQ score in the anakinra
group compared to placebo (-0.25 vs. 0.13; no p-value
reported). Similarly, there was improvement in the ESR
among those who were treated with anakinra (-2.21 vs.
13.73; no p-value reported). The quality was rated poor
because the study did not have a sufficient sample size to
assess efficacy and there was insufficient reporting of ran-
domization and concealment.
Etanercept
Two studies evaluated etanercept versus placebo. One
good-quality randomized discontinuation trial evaluated
children with a polyarticular, pauciarticular, or systemic
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who received etanercept had a flare (28% vs. 81%; p =
0.003). There was also an improvement in the CHAQ
s c o r e( - 0 . 8v s .- 0 . 1 ) .O v e r a l l ,t h e r ew a sa5 4 %m e d i a n
improvement among those who received etanercept com-
pared to no median change in the placebo group. There
was an overall improvement in the number of active joints
(7 vs. 13; no p-value reported), physician global assessment
(2 vs. 5; no p-value reported), parent global assessment (3
vs. 5; no p-value reported), ESR (18 vs. 30; no p-value
reported), and the ACR Pediatric 50 response (72% vs.
23%; no p-value reported).
The other study of etanercept was a fair-quality ran-
domized controlled trial (RCT) that evaluated efficacy
for the treatment of uveitis among children with JRA
[10]. During the study, 6 of 12 subjects in the test treat-
ment arm and 2 of 5 subjects in the conventional treat-
ment arm improved. This was described by study
investigators as no apparent difference.
Infliximab
One fair-quality RCT compared infliximab to conven-
tional treatment among 121 children with polyarticular,
pauciarticular, or systemic JRA [11]. The study did not
find statistically significant differences between
Figure 1 Literature flow diagram. This figure describes the flow of literature for the original AHRQ-sponsored CER, which included one key
question not considered in the present report. Citations were not separated out by key question until the full-text screening stage. Reasons for
exclusion are available in Appendix F of Reference 1.
Kemper et al. BMC Pediatrics 2012, 12:29
http://www.biomedcentral.com/1471-2431/12/29
Page 4 of 10infliximab and conventional treatment in the ACR
Pediatric 50 response at 14 weeks (50% vs. 33.9%,
respectively; p = 0.13) or the rate of clinical remission at
52 weeks (44.1% vs. 43.1%, respectively).
Intravenous Immunoglobulin (IVIG)
Three studies compared IVIG to conventional treatment.
One fair-quality randomized discontinuation trial [12] of
19 patients who had polyarticular JRA found a 3%
decrease in the active joint count among those who were
treated compared to a 30% increase in the placebo group.
Physician global assessment improved for 3% of patients
in the treatment group and worsened for 91% in the pla-
cebo group. Another, poor-quality study [13] compared
IVIG to methylprednisolone among 20 subjects with JCA.
Investigators found no statistically significant difference
between the IVIG and methylprednisolone groups for ESR
(59 at baseline and 21 at 6 months vs. 61 at baseline and
24 at 6 months, respectively). This study was rated poor
because it was an open-label trial with no randomization,
the subjects were incompletely described, and the analyses
were not adjusted for baseline differences.
A poor-quality RCT [14] that included 31 subjects with
systemic JRA found that IVIG compared to conventional
therapy was associated with a non-statistically significant
improvement in the median change in active joint count
(-2 vs. -1) and in physician global assessment of improve-
ment (50% improvement vs. 27% improvement; p > 0.3).
This study was rated poor because the sample size was
small, there was a high dropout rate.
Tocilizumab
O n ef a i r - q u a l i t yr a n d o m i z e dd iscontinuation trial of 43
subjects with JIA evaluated tocilizumab [15]. From the
RCT component, the active joint count in the tocilizumab
group decreased from 3.5 to 0. Similarly, in the conven-
tional treatment group it decreased from 4 to 0. There was
improvement in the CHAQ score for each group (-0.5 vs.
-0.25). Both physician global assessment (51.0 to 5.5 vs. 51
to 14) and parent global assessment (51.0 to 4.5 vs. 55 to
39) improved. The ESR decreased for both the tocilizumab
and conventional treatment group (35 to 0.1 vs. 38 to 15,
respectively). The ACR Pediatric 70 response increased in
the tocilizumab group from approximately 70% to
Figure 2 Treatment comparisons evaluated in the efficacy studies.
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treatment group from approximately 80% to approxi-
mately 30%.
Non-biologic DMARDs vs. Conventional treatment with or
without Methotrexate
Azathioprine
One fair-quality RCT evaluated azathioprine among 32
subjects with polyarticular-onset, pauciarticular-onset, or
systemic-onset JRA [16]. At 16 weeks of treatment, this
study found non-statistically significant improvements
with azathioprine in the number of active joints (-7 vs. -1;
p = 0.45), physician global assessment (-5 vs. -2; p = 0.12),
and the proportion with 50% improvement in ESR (4/13
subjects vs. 2/11 subjects; p = 0.36).
Hydroxychloroquine
Two RCTs evaluated hydroxychloroquine. One good-qual-
ity trial of 162 subjects with polyarticular, pauciarticular,
or systemic JRA (described in two publications [17,18])
found no significant difference in the change in mean
active joint count compared to placebo after 12 months
(6.7 [95% confidence interval (CI) -9.4 to -4] vs. -5.4 [95%
CI -8 to -2.8]). The physician global assessment appeared
slightly better for hydroxychloroquine than for placebo
(70% better, 26% same, 2% worse compared to 53% better,
41% same, 6% worse; no p-value reported). There was no
difference in the mean ESR decrease at 12 months (10
each).
The other study was a poor-quality, open-label RCT of
72 subjects with polyarticular or pauciarticular JRA that
compared hydroxychloroquine to gold [19]. At 50 weeks,
there were no statistically significant differences in the
active joint count (-4 vs. -5), median change in the physi-
cian global assessment (-8 vs. -9), or change in the ESR
(-12 vs. -11). Similarly, the physician overall assessment of
at least 50% improvement was not statistically significantly
different between the hydroxychloroquine group and the
gold group (12 of 17 improved vs. 10 of 15 improved,
respectively). This study was rated poor because allocation
concealment was not specified, there were important dif-
ferences in baseline characteristics, it was unclear if out-
comes were assessed blinded to the intervention, and the
outcomes were incompletely described.
Methotrexate
Three studies compared methotrexate to conventional
treatment without methotrexate. One good-quality RCT
of 127 subjects with JIA compared low-dose methotrexate,
very low-dose methotrexate, and placebo in a 6-month
trial [20]. The mean active joint count decreased with low-
dose methotrexate (-7.5), very low-dose methotrexate
(-5.2), and placebo (-5.2; p > 0.3 overall). Physician global
assessment improved with low-dose methotrexate com-
pared to placebo (p = 0.02), but there was no statistically
significant difference between the low-dose and very low-
dose methotrexate groups for this outcome (p = 0.06).
Based on a composite index with at least 25% improve-
ment in articular score and improvement according to
physicians and parents, 63% of those in the low-dose
methotrexate group improved, compare to 32% in the very
low-dose methotrexate group, and 36% in the placebo
group (p = 0.013).
Another good-quality study [21] of 88 subjects with
extended oligoarticular or systemic JIA compared metho-
trexate to placebo among children with extended oligoarti-
cular JIA or systemic JIA in a double-blind RCT with
crossover. Among those with oligoarticular JIA, there was
statistically significant improvement in physician global
assessment (p < 0.001) and ESR (p < 0.001) with metho-
trexate. The change in the number of joints with synovitis
(-3) did not achieve statistical significance (p < 0.1). Simi-
larly, among those with systemic JIA, there was improve-
ment in physician global assessment (p < 0.001), but not
in ESR (p = 0.06) or in the number of joints with synovitis
(p = 0.06) in patients taking methotrexate.
A poor-quality, non-randomized study that included 63
children with JIA compared methotrexate to NSAIDs and
to methylprednisolone [22]. In this study, the active joint
count improved more in the methylprednisolone group
than in either the methotrexate or NSAID groups (-7.1 vs.
-4 vs. -0.8, respectively; p = 0.008). This study was rated
poor because there was confounding by indication, the
analysis did not adjust for potential confounders, out-
comes were not assessed blinded to treatment, and sub-
jects were not blinded to treatment assignment.
Penicillamine
Four publications describing three distinct studies evalu-
ated penicillamine. One good-quality RCT [17,18] among
subjects with polyarticular, pauciarticular, or systemic JRA
found no statistically significant effect on the mean active
joint count with penicillamine compared to placebo after
12 months (-3 [95% CI -4.8 to -1.1] vs. -5.4 [-8 to -2.8]);
results were similar for physician global assessment (56%
better, 28% same, 16% worse vs. 53% better, 41% same, 6%
worse) and mean decrease in ESR (9.4 vs. 10).
A fair-quality RCT [23] of 74 subjects with polyarticular-
onset, pauciarticular-onset, or systemic-onset JCA found
no statistically significant effect on ESR in a 6-month
study in patients treated with penicillamine compared to
conventional treatment (-18 vs. -8). However, this study
did find a statistically significant decrease in the number
of painful joints in patients taking penicillamine (-3 vs.
-1.6; p < 0.04).
A previously described poor-quality, open-label RCT
[19] that included 74 subjects with polyarticular or pau-
ciarticular JRA found no statistically significant effect for
penicillamine compared to gold at 50 weeks in the active
joint count (-2.5 vs. -5), median change in the physician
global assessment (-7.5 vs. -9), change in ESR (-8 vs. -11),
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improvement based on physician assessment (8/12 vs.
10/15).
Sulfasalazine
One good-quality RCT of 69 subjects with polyarticular or
oligoarticular JCA evaluated sulfasalazine versus placebo
[24]. In this study, it was unclear which time points were
compared. However, there was statistically significant
improvement with sulfasalazine in active joint count (-5.54
vs. -0.78; p = 0.005), physician global assessment (-1.95 vs.
-0.99; p = 0.0002), patient/parent global assessment (-0.98
vs. -0.44; p = 0.01), and decrease in ESR (-0.74 vs. -0.04;
p < 0.001). The number of improved joints by x-ray find-
ings was not statistically significantly different (0.71 vs.
0.53).
Comparative effects of different DMARDs (key
question 2)
Comparisons of biologic DMARDs
Etanercept vs. Infliximab
One poor-quality, non-randomized, open-label study com-
pared etanercept to infliximab among subjects with poly-
articular JIA [25]. Among the 10 patients receiving
etanercept, one was withdrawn for non-compliance.
Among the 14 patients receiving infliximab, 4 withdrew
because of adverse events and 1 withdrew because of fail-
ure to reach the ACR Pediatric 50 response. After 12
months of treatment, the change in active joint count was
similar between etanercept (-9.5 [95% CI -19 to -3]) and
infliximab (-11.5 [95% CI -17 to -7.5]). Results were also
similar in the two treatment groups for changes in the
CHAQ score (-0.81 vs. -0.31; p = 0.12), physician global
assessment (-29 vs. -35; p = 0.65), patient/parent global
assessment (-24.5 vs. -27.5; p = 0.81), ACR Pediatric 75
(67% each), ACR Pediatric 50 (78% vs. 89%; p-value not
reported, but calculated as 0.53), and ESR (28.5 vs. -25;
p = 0.37). This study was rated poor because assessment
was not described as blinded to treatment.
Comparisons of non-biologic DMARDs
Penicillamine vs. Hydroxychloroquine
Two publications [17,18] described a good-quality RCT
that compared penicillamine and hydroxychloroquine to
placebo (results described above, under Key Question 1)
and to one another. At 12 months, neither active drug
was superior to the other based on active joint count,
ESR, or physician global assessment.
One poor-quality, open-label RCT [19] compared
hydroxychloroquine and penicillamine to gold (results
described above, under Key Question 1) and to one
another. At 50 weeks, there were no significant differ-
ences between the two DMARDs in active joint count,
physician global assessment, or ESR.
Sulfasalazine vs. Hydroxychloroquine
One poor-quality RCT compared sulfasalazine to hydroxy-
chloroquine in 39 subjects with oligoarticular-onset, poly-
articular-onset, or systemic-onset JCA [26]. After 6
months, the average number of affected joints decreased
by 1.5 in the sulfasalazine group and by 0.6 in the hydro-
xychloroquine group (no p-value reported). During this
time, the ESR decreased in both the sulfasalazine group
(52.7 to 36.3; no p-value reported) and hydroxychloro-
quine group (41.2 to 28.9; no p-value reported). Physician
global assessment and patient global assessment were
similar in the two groups. This study was rated as poor
because there was incomplete description of the subjects
and it was unclear if treatment and assessment were
blinded.
Leflunomide vs. Methotrexate
One good-quality RCT compared leflunomide to conven-
tional treatment with methotrexate in 94 subjects with
polyarticular JRA [27]. This 16-week study with a 32-week
blinded extension found improvements in both groups
with no significant differences by treatment. The active
joint count decreased for the leflunomide and conven-
tional treatment groups (-8.1 vs. -8.9; p = not significant).
Similarly, in both groups there were improvements in the
CHAQ score (-0.44 vs. -0.39; p = not significant), physi-
cian global assessment (-31.5 vs. -32.1; p = not significant),
parent global assessment (-15.9 vs. -22; p = not signifi-
cant), and ESR (-6.5 vs. 7.2; p = not significant). As the
trial proceeded, the methotrexate group appeared to have
a greater improvement in the proportion of patients who
had an ACR Pediatric 30, Pediatric 50, or Pediatric 70
response. For example, 70% of the leflunomide group and
83% of the methotrexate group achieved an ACR Pediatric
70 response at 48 vs. 16 weeks. The improvement was not
statistically significant for either the leflunomide (p = 0.88)
or methotrexate (p = 0.06) groups.
Serious adverse events (key question 3)
The search identified 151 publications, including 19
RCTs, which reported adverse events possibly associated
with a DMARD among patients with JIA. Although these
reports described 4344 patients, there was insufficient
information to determine whether some patients were
included in more than one report. Furthermore, some
series included patients who were adults or who did not
have JIA. Thirteen of the 19 RCTs, representing 914
unique patients treated with 14 DMARDs or DMARD
combinations, included placebo comparisons. With the
exception of one patient who died 10 days after receiving
a placebo infusion but who had also received methotrex-
ate, none of these RCTs reported incident cases of either
cancer or death among patients receiving a DMARD dur-
ing the RCT phase of the study.
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sented in the eligible studies that reported adverse events,
11 incident cases of cancer were reported. One case of
thyroid carcinoma was associated with etanercept [28],
one case of thyroid carcinoma was associated with etaner-
cept plus methotrexate [29], and one case of yolk sac car-
cinoma was associated with etanercept plus methotrexate
[29]. The remaining eight incident cases of cancer were
lymphomas: two cases with etanercept plus methotrexate
[29,30]; two cases in patients who had received infliximab,
etanercept, and methotrexate [30]; three cases with meth-
otrexate alone; and one case with methotrexate and
cyclosporine A, which was diagnosed at autopsy after
death attributed to Legionella pneumonia [31-34]. Insuffi-
cient data are available to assess the impact of duration of
treatment on the risk of having a serious adverse event.
Efficacy, effectiveness, safety, and adverse effects
across different diagnostic categories of JIA (key
question 4)
One study compared the efficacy of the DMARD stu-
died (methotrexate) across different diagnostic cate-
gories of JIA [21]. There was no statistically significant
difference in the efficacy of methotrexate for oligoarticu-
lar JIA versus systemic JIA. No data on adverse events
was provided.
Discussion
Few data are available to evaluate the comparative effec-
tiveness of DMARDs. Methotrexate is the most studied
DMARD and good-quality studies support its efficacy.
The paucity of evidence precludes direct comparisons of
the other, newer DMARDs against each other.
Research on the effectiveness of treatments for JIA is
challenging because it includes multiple categories that
could potentially respond differently to therapy. Further-
more, the health impact of JIA fluctuates over time.
Despite this, our review found that based on the overall
number, quality, and consistency of studies, there is mod-
erate strength of evidencet os u p p o r tt h a tD M A R D s
improve symptoms associated with JIA. However, the
strength of evidence is low that DMARDs improve overall
health status.
There was significant variation in how outcomes were
reported. For example, among the six randomized discon-
tinuation trials, four reported laboratory measures of
inflammation [6,8,9,15], four reported whether a flare
occurred [6-9], three reported active joint count [6,12,15],
and four reported quality of life based on the CHAQ
[6,8,9,15]. Of those that reported CHAQ score, one [9]
reported only the percentage change from baseline, and
two [8,15] gave only average values without measures of
dispersion. Standardizing outcome measures used in stu-
dies would allow for direct comparisons and patient-level
meta-analysis. Ideally, these outcome measures should be
clinically relevant and feasible to measure in both research
and non-research settings. Such measures would help
patients, families, and healthcare providers evaluate treat-
ment options.
This review identified the important need for trials
evaluating the effectiveness of DMARDs versus both
conventional therapy and other DMARDs across cate-
gories of JIA. Factorial designs involving multiple treat-
ments are a potential solution to challenge of low
sample sizes in studies of rare conditions. In addition,
patient-level meta-analysis of treatment outcomes could
increase sample sizes, but only if trials are designed to
include similar outcome measures.
There is a lack of information on adverse events asso-
ciated with DMARDs in children with JIA. However, our
findings suggest that short-term mortality associated with
DMARDs is low. Because adverse events may not occur in
the short time periods used in drug trials, the development
of registries of patients treated with DMARDs may be
necessary to accurately assess both risks and benefits [35].
Until such registries are available, assessment of other
sources of data will be important [35]. For example, a
recent report that combined a review of the literature with
drug company-sponsored post-marketing database sug-
gests that the risk of any malignancy with etanercept,
regardless of indication, is about 0.02 per 100 patient-years
among patients 4 to 17 years of age, compared to 0.015
among the general population of children 4 to 17 years of
age in the United States [36]. Of course, patients, families,
and physicians will need to make important treatment
decisions before these new data systems are available.
Conclusions
JIA is an important cause of morbidity. Few data are
available to evaluate the comparative effectiveness of
either specific DMARDs or general classes of DMARDs.
Moderately strong evidence supports that DMARDs
improve the symptoms associated with JIA. Limited data
suggest that short-term risk of cancer is low. To support
shared decision-making around the use of DMARDs
based on these findings, educational material for
patients and families [37] and clinicians [38] has been
developed by AHRQ.
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